Shares of Becton, Dickinson and Company (NYSE:BDX) have been given an average recommendation of “Buy” by the sixteen brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $193.42.

A number of brokerages have issued reports on BDX. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price target for the company from $186.00 to $200.00 in a research note on Monday, April 24th. Barclays PLC reiterated an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Finally, Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, July 17th.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Given Average Rating of “Buy” by Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/18/becton-dickinson-and-company-bdx-given-average-rating-of-buy-by-brokerages.html.

Becton, Dickinson and (NYSE BDX) opened at 199.31 on Friday. The company’s 50-day moving average price is $199.60 and its 200 day moving average price is $188.53. The firm has a market capitalization of $45.36 billion, a PE ratio of 57.72 and a beta of 1.05. Becton, Dickinson and has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period last year, the company posted $2.35 EPS. On average, analysts forecast that Becton, Dickinson and will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. Becton, Dickinson and’s payout ratio is currently 83.43%.

In other news, insider Nabil Shabshab sold 6,149 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $201.76, for a total value of $1,240,622.24. Following the completion of the sale, the insider now owns 15,648 shares in the company, valued at $3,157,140.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold 57,631 shares of company stock valued at $11,112,178 in the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Koch Industries Inc. raised its stake in Becton, Dickinson and by 45,268.7% in the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after buying an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC acquired a new stake in Becton, Dickinson and during the second quarter worth about $225,164,000. Finally, Janus Henderson Group PLC raised its stake in Becton, Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after buying an additional 1,122,191 shares during the last quarter. Institutional investors own 75.57% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.